Understanding how specific proteins affect DNA repair in aggressive breast cancer
Official title: Deciphering functions of the ATR-METTL3-BRCA1 Axis in genome instability and Tumorigenesis
Funded at Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NIH-11098543 · Data updated 2026-11-12
This study is looking at how certain proteins help fix DNA damage in aggressive breast cancers, like triple negative breast cancer, to find new ways to improve treatment for patients based on their unique genetic makeup.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center NIH-funded |
| Lab location | 1 site (Torrance, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $460,015 |
| NIH project number | 5R01CA288736-02 |
| Project ID | NIH-11098543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple negative breast cancer or those with BRCA1 mutations.
✕Less likely to help
Patients with non-aggressive forms of breast cancer or those without BRCA1 mutations may not benefit from this research.
What this research studies
This research investigates the role of the ATR-METTL3-BRCA1 axis in DNA damage repair, particularly in aggressive forms of breast cancer like triple negative breast cancer (TNBC). By examining how these proteins interact and contribute to genome stability, the study aims to uncover new therapeutic targets that could improve treatment outcomes. The approach involves analyzing the mechanisms by which BRCA1 and its partners respond to DNA damage, which is crucial for developing targeted therapies. Patients may benefit from insights gained about how to better treat their cancer based on their genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive breast cancer, particularly those with BRCA1 mutations.
How similar studies have gone: Previous research has shown promising results in targeting BRCA1 mutations in breast cancer, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, United States Active
Researchers
- Principal investigator: Wang, Hua — Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Study coordinator: Wang, Hua
Related research
Other NIH-funded projects on the same topics.
-
Immunometabolic and epigenetic changes in the mouth’s immunity in diabetes-related thrush
This grant looks at why people with diabetes get a higher risk of oral thrush and how high blood sugar affects the mouth’s defenses against Candida albicans.
-
Non-invasive heart fat markers to predict ASCVD risk
Aging adults who don’t yet have heart disease may get a clearer picture of their risk by using CT scans to study fat around the heart and arteries.
-
Asthma and IgE: How nerve signals in the lungs may boost allergy antibodies
A short, patient-friendly study will explore how a nerve-released substance called substance P may push immune cells to make more allergy-causing IgE in asthma.
-
Time-limited trials to guide care for seriously ill patients in the ICU
A real-world study tests using structured, time-limited conversations and agreed-upon treatment plans to help seriously ill patients and their families avoid non-beneficial ICU care.
-
Cellular aging and lung disease in Down syndrome babies and adults
A study will explore how aging cells may drive lung problems in people with Down syndrome from birth through adulthood.
-
New CPET approach to tell apart heart problems from muscle weakness
A doctor-guided study tests a modified cardiopulmonary exercise test that adds simple muscle-power measurements to better tell whether shortness of breath comes from heart disease or from weak, fatigued muscles.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.